Key Takeaway: Cognition Therapeutics is set to report its financial results for the second quarter of 2024. The announcement indicates a routine update on the company's financial performance. No specific details about the results or expectations have been provided in the article.
Price reaction · baseline $0.7286 (2024-08-02 close) · hit pre-market · 3 other CGTX headline(s) in the window, move may be shared
day 0 close
-10%
day 1
-11.5%
day 3 · peak
-19.8%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.